A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes had larger decreases in HbA1c at 28 weeks with mazdutide vs. dulaglutide. More than ...

Please provide your email address to receive an email when new articles are posted on . Tirzepatide prevented cardiovascular events similarly to dulaglutide in patients with diabetes and heart disease ...

The diabetes drug dulaglutide (Trulicity) may significantly lower a woman’s risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...